Anemia Drugs Market Report 2025

The anemia drugs market size has grown strongly in recent years. It will grow from $14.72 billion in 2024 to $15.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising awareness of iron deficiency anemia, rise in geriatric population, increasing healthcare access in developing regions, and rising demand for targeted therapies.

The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $21.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising healthcare expenditure in emerging markets, growing number of clinical trials in anemia treatment, rise in global prevalence of anemia, and increasing focus on patient-centric drug development. Major trends in the forecast period include advancement in gene therapy for anemia, advanced delivery systems for iron supplements, innovation in erythropoiesis-stimulating agents, advanced diagnostic tools for anemia detection, and innovation in oral anemia treatments.

The forecast of 7.5% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. nephrology practices by driving up costs of iron replacement therapies sourced from Spain and France, exacerbating chronic kidney disease-related anemia expenses and increasing dialysis center burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing emphasis on personalized medicine is expected to drive the expansion of the anemia drugs market moving forward. Personalized medicine is a healthcare approach that customizes treatment and medical decisions based on an individual’s genetic makeup, lifestyle, and environment. This increased focus is largely due to advancements in genomic sequencing, which enable more accurate identification of genetic variations linked to diseases and treatment responses. Personalized medicine supports the development of anemia drugs by allowing treatments to be tailored according to individual genetic profiles, thereby enhancing drug effectiveness and reducing adverse effects for improved patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial rise from 6 approvals in 2022. Thus, the rising focus on personalized medicine is contributing to the growth of the anemia drugs market.

Key companies in the anemia drugs market are concentrating on innovative drug development, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), which aim to improve iron metabolism and boost red blood cell production for more effective anemia therapies. Oral HIF-PHI medications inhibit prolyl hydroxylase enzymes that regulate the hypoxia-inducible factor (HIF) pathway. For instance, in February 2023, GSK plc, a UK-based pharmaceutical company, introduced Jesduvroq, a treatment designed to enhance red blood cell production and treat anemia in adult patients with chronic kidney disease. This advanced anemia drug improves iron metabolism and red blood cell production while supporting personalized therapy approaches. Jesduvroq is highly effective at increasing red blood cell production and managing anemia in chronic kidney disease patients by optimizing iron metabolism for better therapeutic results.

In May 2023, Akebia Therapeutics, a U.S.-based biopharmaceutical company, partnered with Medice Arzneimittel Pütter GmbH & Co. KG to commercialize Vafseo for anemia treatment in Europe and Australia. Through this collaboration, Akebia Therapeutics and Medice Arzneimittel Pütter aim to promote sustainable growth and improve the accessibility of Vafseo by expanding its availability and fostering innovation. Medice Arzneimittel Pütter GmbH & Co. KG is a Germany-based pharmaceutical company specializing in anemia treatments and prescription medicines.

Major players in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.

North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anemia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anemia drugs market consists of sales of androgens, hydroxyurea, luspatercept and sotatercept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The anemia drugs market research report is one of a series of new reports that provides anemia drugs market statistics, including anemia drugs industry global market size, regional shares, competitors with an anemia drugs market share, anemia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anemia drugs industry. This anemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anemia drugs are used to treat low levels of red blood cells (RBCs) or hemoglobin in the blood. These medications enhance oxygen transport throughout the body and help alleviate fatigue by addressing the root causes of anemia, such as iron deficiency, chronic illnesses, or kidney problems.

The main categories of anemia drugs include dietary supplements and medications. Dietary supplements are oral products that provide essential nutrients like iron, folic acid, or vitamin B12 to help manage or prevent anemia. Treatment approaches consist of oral iron therapy, parenteral iron therapy, red blood cell transfusions, and other supportive care options. The different types of anemia treated include iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and other forms. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. The primary end-users include clinics, healthcare facilities, and home healthcare providers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.